<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11860374</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.717</article-id><article-id pub-id-type="other">EPP0612</article-id><article-id pub-id-type="pii">S092493382400717X</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Half a Decade of Intravenous Ketamine Administration: Our Observation Results and Insights regarding its safety</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Argitis</surname><given-names>P.</given-names></name><xref rid="aff1710" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Karampas</surname><given-names>A.</given-names></name><xref rid="aff1710" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Peyioti</surname><given-names>M.</given-names></name><xref rid="aff1710" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor0578" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Koukouras</surname><given-names>T.</given-names></name><xref rid="aff1710" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Karavia</surname><given-names>S.</given-names></name><xref rid="aff1710" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chaviaras</surname><given-names>Z.</given-names></name><xref rid="aff1710" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff1710"><sup>1</sup>Psychiatric, <institution>General Hospital of Corfu</institution>, <city>Corfu</city>, <country>Greece</country></aff><author-notes><corresp id="cor0578"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="692">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S347</fpage><lpage>S348</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S092493382400717Xa.pdf"/><abstract><sec id="sec3474"><title>Introduction</title><p>Ketamine, originally an anesthetic, has emerged as a potent tool in the fight against treatment-resistant depression and suicide. Clinical trials have demonstrated its ability to induce remission of severe depressive symptoms, with effects that can extend over several weeks.Furthermore, research highlights Ketamine&#x02019;s potential to rapidly reduce suicidal ideation. This suggests Ketamine&#x02019;s role as an intervention in suicide prevention, especially when conventional treatments prove ineffective. While isolated cases report severe respiratory depression, primarily when combined with other medications, most incidents involve temporary apneic episodes following high-dose intravenous administration. Understanding Ketamine&#x02019;s safety profile is vital for its clinical optimization and ensuring patient well-being during use</p></sec><sec id="sec3475"><title>Objectives</title><p>This presentation serves to describe, and evaluate our clinic&#x02019;s safety protocol implemented for intravenous (IV) Ketamine infusions at the General Hospital of Corfu. Our primary goal is to rigorously assess the safety and tolerability of IV Ketamine in a clinical setting</p></sec><sec id="sec3476"><title>Methods</title><p>Patients must meet stringent criteria:<list list-type="bullet"><list-item><p>Exclude those over 70.</p></list-item><list-item><p>MMSE score above 25.</p></list-item><list-item><p>Controlled blood pressure.</p></list-item><list-item><p>No cardiac insufficiency, myocardial ischemia, or high intraocular/intracranial pressure.</p></list-item><list-item><p>Absence of thyrotoxicosis, psychosis, or seizures.</p></list-item></list></p><p>Pre-infusion comprehensive evaluation:<list list-type="bullet"><list-item><p>Includes ECG, blood biochemistry studies, and frequent blood pressure checks.</p></list-item><list-item><p>Requires a 2-hour
fast.</p></list-item></list></p><p>Ketamine infusion:<list list-type="bullet"><list-item><p>IV Ketamine administered at 0.5mg/kg in 100ml N/S.</p></list-item><list-item><p>Continuous monitoring of oxygen saturation (PO2) and cardiac rhythm.</p></list-item><list-item><p>Blood pressure checks every 15 minutes.</p></list-item></list></p><p>Treatment typically involves 7 sessions over a span of a month, with an initial test dose of 0.25 mg/kg.</p></sec><sec id="sec3477"><title>Results</title><p>Ketamine infusions were administered to a total of 208 patients. The majority of participants experienced a slight increase in blood pressure, while there were no significant changes in cardiac rhythm. Additionally, almost all patients reported experiencing dizziness or headaches during the infusion. Notably, nearly half of the patients reported an alteration in taste perception as a side effect. It&#x02019;s important to highlight that all observed side effects, spontaneously resolved within an hour after the conclusion of the infusion. However, in a small subset of cases (six instances), the side effects were severe enough to necessitate the premature termination of the ketamine infusion</p></sec><sec id="sec3478"><title>Conclusions</title><p>
Although ketamine demonstrates a favorable safety profile with minimal major side effects when administered following our established safety protocol. However, we want to underscore the critical importance of vigilant patient monitoring during ketamine administration and the prompt addressing of any adverse effects. This proactive approach is paramount to ensure the safety and overall well-being of patients receiving ketamine treatment</p></sec><sec id="sec3479"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>